NASDAQ:MACK Merrimack Pharmaceuticals (MACK) Stock Forecast, Price & News $12.24 +0.02 (+0.16%) (As of 09/22/2023 08:52 PM ET) Add Compare Share Share Today's Range$12.14▼$12.4050-Day Range$11.60▼$12.4952-Week Range$3.00▼$13.66Volume26,100 shsAverage Volume101,952 shsMarket Capitalization$175.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Merrimack Pharmaceuticals MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish7.47% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingAcquiring Shares$1.64 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.0.86 out of 5 starsMedical Sector953rd out of 962 stocksPharmaceutical Preparations Industry451st out of 453 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Merrimack Pharmaceuticals. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.47% of the outstanding shares of Merrimack Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMerrimack Pharmaceuticals has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.Change versus previous monthShort interest in Merrimack Pharmaceuticals has recently decreased by 2.73%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMerrimack Pharmaceuticals does not currently pay a dividend.Dividend GrowthMerrimack Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MACK. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Merrimack Pharmaceuticals this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for MACK on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Merrimack Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,638,956.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders28.87% of the stock of Merrimack Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions55.90% of the stock of Merrimack Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Merrimack Pharmaceuticals is -111.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Merrimack Pharmaceuticals is -111.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMerrimack Pharmaceuticals has a P/B Ratio of 8.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Merrimack Pharmaceuticals (NASDAQ:MACK) StockMerrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.Read More MACK Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MACK Stock News HeadlinesSeptember 20, 2023 | americanbankingnews.comMerrimack Pharmaceuticals (NASDAQ:MACK) Stock Price Crosses Above 200 Day Moving Average of $12.23September 20, 2023 | americanbankingnews.comMerrimack Pharmaceuticals (NASDAQ:MACK) Stock Price Passes Above Two Hundred Day Moving Average of $12.23September 25, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.August 15, 2023 | finance.yahoo.comWestern Standard LLC Boosts Stake in Merrimack Pharmaceuticals IncAugust 13, 2023 | insidermonkey.comOnconova Therapeutics, Inc. (NASDAQ:ONTX) Q2 2023 Earnings Call TranscriptAugust 3, 2023 | finance.yahoo.comMerrimack Reports Second Quarter 2023 Financial ResultsJuly 18, 2023 | finanznachrichten.dePharming Group N.V.: Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the BoardJuly 18, 2023 | finance.yahoo.comPharming to nominate industry leader Dr. Richard Peters as new Chairman of the BoardSeptember 25, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.April 19, 2023 | finance.yahoo.comRetail investors account for 38% of Merrimack Pharmaceuticals, Inc.'s (NASDAQ:MACK) ownership, while hedge funds account for 33%April 16, 2023 | marketwatch.comGlobal Receptor Tyrosine Protein Kinase ERBB 3 Market Size Emerging Trends and Will Generate New Growth Opportunities Status 2030 By VMReportsApril 15, 2023 | usnews.comMerrimack Valley High SchoolApril 3, 2023 | thestreet.comWhy Merrimack Pharmaceuticals (MACK) Stock is Down in After-Hours Trading TodayMarch 30, 2023 | nytimes.comTrack Covid-19 in Merrimack County, New HampshireMarch 22, 2023 | marketwatch.comOncology Injection Drug Market Size and Forecast till 2031March 15, 2023 | msn.comWhy Jounce Therapeutics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving PremarketMarch 10, 2023 | nytimes.comMerrimack Won a Title, but the N.C.A.A. Tournament Will Have to WaitMarch 9, 2023 | msn.comHistogen GAAP EPS of -$3.46, revenue of $3.77M misses by $0.35MMarch 9, 2023 | finance.yahoo.comMerrimack Reports Full Year 2022 Financial ResultsMarch 7, 2023 | yahoo.comMerrimack, United States - Weather Forecasts | Maps | News - Yahoo WeatherFebruary 24, 2023 | uk.finance.yahoo.comThe Global Liposomal Products Market is forecast to grow by $3,183.63 mn during 2022-2027, accelerating at a CAGR of 9.65% during the forecast periodFebruary 22, 2023 | finance.yahoo.comRadionetics Oncology Appoints Istvan Molnar, M.D. as Chief Medical OfficerFebruary 19, 2023 | marketwatch.comGlobal HER2-Positive Breast Cancer Market to by In-depth Analysis of Revenue Forecast and Competitive Landscape 2030 By VMReportsDecember 13, 2022 | finance.yahoo.comBullish Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) insiders filled their treasuries with US$574k worth of stock over last yearDecember 5, 2022 | finance.yahoo.comMerrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights PlanNovember 16, 2022 | finance.yahoo.comBiotech Stock Roundup: MACK Up on Study Data, MRNA Offers Vaccine Update & MoreNovember 10, 2022 | finance.yahoo.comHedge funds investors control 44% of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) and were rewarded last week after stock increased 228%See More Headlines Receive MACK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address MACK Company Calendar Last Earnings8/03/2023Today9/24/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:MACK CUSIP59032810 CIK1274792 Webwww.merrimackpharma.com Phone617-720-8606Fax617-491-1386Employees426Year Founded2000Profitability EPS (Most Recent Fiscal Year)($0.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,540,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-9.04% Return on Assets-8.80% Debt Debt-to-Equity RatioN/A Current Ratio47.30 Quick Ratio47.30 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.44 per share Price / Book8.50Miscellaneous Outstanding Shares14,320,000Free Float10,187,000Market Cap$175.28 million OptionableOptionable Beta1.76 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Gary L. Crocker M.B.A. (Age 71)MBA, Pres, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman Comp: $76kDr. Ulrik B. Nielsen Ph.D. (Age 51)Co-Founder & Independent Director Comp: $72.5kDr. Anthony J. Sinskey Ph.D. (Age 83)Sc.D., Co-Founder and Scientific Advisor Geoffrey Grande C.F.A.Sr. Director of CommunicationsMs. Ellen K. Forest (Age 59)Head of HR Dr. Daryl C. Drummond Ph.D. (Age 54)Head of Research Mr. Timothy R. Surgenor (Age 63)Sec. More ExecutivesKey CompetitorsXOMANASDAQ:XOMARigel PharmaceuticalsNASDAQ:RIGLEmergent BioSolutionsNYSE:EBSVerastemNASDAQ:VSTMVanda PharmaceuticalsNASDAQ:VNDAView All CompetitorsInsiders & InstitutionsCalifornia State Teachers Retirement SystemBought 3,483 shares on 8/21/2023Ownership: 0.024%Goldman Sachs Group Inc.Sold 20,756 shares on 8/15/2023Ownership: 0.099%Citadel Advisors LLCSold 14,600 shares on 8/15/2023Ownership: 0.000%Wells Fargo & Company MNBought 4,276 shares on 8/15/2023Ownership: 0.031%Lazard Asset Management LLCSold 1,828 shares on 8/15/2023Ownership: 0.022%View All Insider TransactionsView All Institutional Transactions MACK Stock - Frequently Asked Questions How have MACK shares performed in 2023? Merrimack Pharmaceuticals' stock was trading at $11.46 at the start of the year. Since then, MACK shares have increased by 6.8% and is now trading at $12.24. View the best growth stocks for 2023 here. When is Merrimack Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our MACK earnings forecast. How were Merrimack Pharmaceuticals' earnings last quarter? Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) posted its quarterly earnings data on Thursday, August, 3rd. The biopharmaceutical company reported ($0.03) EPS for the quarter. When did Merrimack Pharmaceuticals' stock split? Merrimack Pharmaceuticals shares reverse split on the morning of Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Merrimack Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Rite Aid (RAD), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Novavax (NVAX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Bausch Health Companies (BHC) and Verastem (VSTM). What is Merrimack Pharmaceuticals' stock symbol? Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK." Who are Merrimack Pharmaceuticals' major shareholders? Merrimack Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.72%), Dimensional Fund Advisors LP (3.21%), Geode Capital Management LLC (1.70%), Wittenberg Investment Management Inc. (1.43%), State Street Corp (1.22%) and Northern Trust Corp (0.81%). Insiders that own company stock include Ana Radeljevic, Eric Andersen, Gary L Crocker, Noah G Levy and Ulrik B Nielsen. View institutional ownership trends. How do I buy shares of Merrimack Pharmaceuticals? Shares of MACK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Merrimack Pharmaceuticals' stock price today? One share of MACK stock can currently be purchased for approximately $12.24. How much money does Merrimack Pharmaceuticals make? Merrimack Pharmaceuticals (NASDAQ:MACK) has a market capitalization of $175.28 million. The biopharmaceutical company earns $-1,540,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. How many employees does Merrimack Pharmaceuticals have? The company employs 426 workers across the globe. How can I contact Merrimack Pharmaceuticals? Merrimack Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The official website for the company is www.merrimackpharma.com. The biopharmaceutical company can be reached via phone at 617-720-8606, via email at ir@merrimack.com, or via fax at 617-491-1386. This page (NASDAQ:MACK) was last updated on 9/25/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merrimack Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.